Introduction: Patients with complex pelvic fractures with uncontrollable haemorrhage have a very mortality from pelvic haemorrhage and associated injuries. Management remains controversial and includes an number of techniques including pelvic stabilisation, angiography and direct surgical control of haemorrhage. Packing the pelvic cavity is a technique used rarely in this situation but is popular to control haemorrhage from other sources in similar situations. We have reviewed our experience of pelvic packing for uncontrollable haemorrhage to assess the effectiveness of this technique.

Materials & Methods: From a prospectively gathered database of 132 patients with significant pelvic fractures admitted between April 2002 and December 2005, 8 patients (5 males and 3 females) with an average age of 52.9 yrs were identified who underwent pelvic stabilisation and packing as an emergent life saving procedure for uncontrolled haemorrhage associated with pelvic fracture. Basic data including their presenting vital signs, pelvic fracture pattern and associated injuries were recorded. All were subject to pelvic stabilisation packing and their subsequent clinical course including their transfusion requirements and additional management was also assessed

Results: 6 out of these 8 patients died, 5 within the first 24 hrs after injury and one after 14 days from sepsis & MOF/MODS. The exact source of bleed could not be identified in any of these patients and was assumed to be venous and from large fractured bony surfaces. 4 patients had angiography and embolisation in addition and 2 of these survived.

Conclusion: The mortality of haemodynamically unstable pelvic fractures remains high and all modalities of treatment should be used to control bleeding. Pelvic packing may form an important part in the armamentarium of haemostatic measures; its role, however, needs to be better defined by larger multi-centre studies. Although difficult to conclude, the pelvic packing may have been responsible for reducing the mortality in this subgroup from a 100% to 75%.

This prospective randomized multicenter study compares two methods of bone defect treatment in tibial plateau fractures: a bioresorbable calcium phosphate paste (Alpha-BSM) that hardens at body temperature to give structural support versus Autogenous iliac bone graft (AIBG).

One hundred and eighteen patients were enrolled with a 2:1 randomization, Alpha-BSM to AIBG. There was a significant increased rate of non-graft related adverse affects and a higher rate of late articular subsidence (three to nine month period) in the AIBG group.

A bioresorbable calcium phosphate material is recommended in preference to the gold standard of AIBG for bone defects in tibial plateau fractures.

This prospective randomized multicenter study was undertaken to compare two methods of bone defect treatment: a bioresorbable calcium phosphate paste (Alpha-BSM –DePuy, Warsaw, IN) that hardens at body temperature to give structural support and is gradually resorbed by a cell-mediated bone regenerating mechanism versus Autogenous iliac bone graft (AIBG).

One hundred and eighteen adult acute closed tibial plateau fractures, Schatzker grade two to six were enrolled prospectively from thirteen study sites in North America from 1999 to 2002. Randomization occurred at surgery with a FDA recommendation of a 2–1 ratio, Alpha BSM (seventy-eight fractures) to AIBG (forty fractures). Only internal fixation with standard plate and screw constructs was permitted. Follow-up included standard radiographs and functional studies at one year, with a radiologist providing independent radiographic review.

The two groups exhibited no significant differences in randomization as to age, sex, race, fracture patterns or fracture healing. There was however, a significant increased rate of non-graft related adverse affects in the AIBG group. There was an unexpected significant finding of a higher rate of late articular subsidence in the three to nine month period in the AIBG group.

Recommendations for the use of AIBG for bone defects in tibial plateau fractures should be discouraged in favor of bioresorbable calcium phosphate material with the properties of Alpha BSM. We believe further randomized studies using AIBG as a control group for bone defect support of articular fractures are unjustified.

A bioresorbable calcium phosphate material is recommended in preference to the gold standard of AIBG for bone defects in tibial plateau fractures.

Funding: DePuy, Warsaw, IN.